



Revolutionizing  
precision heartcare






# Ingenuity Applied



HeartFlow brings together human ingenuity and advanced technology to help combat heart disease, the leading cause of death.

HeartFlow's non-invasive, **personalized cardiac test** provides unprecedented visualization of each patient's coronary arteries, enabling physicians to **create more effective treatment plans** for their patients.




# Superior Quality



By combining review from expert analysts, who have over 500,000 hours of collective experience, with AI-powered algorithms trained on millions of CT images, HeartFlow is bringing a new level of precision to non-invasive detection of heart disease.

- » **2x more likely to identify disease than other tests<sup>1</sup>**
- » **Low false negative and false positive rates in real-world clinical use<sup>2</sup>**
- » **“Core Lab” quality control monitoring program with over 10,000 measurements<sup>2</sup>**



# Clinical Excellence



Since inception, HeartFlow has been committed to producing comprehensive clinical evidence supporting the diagnostic accuracy, safety, efficacy, cost-effectiveness, and utility of its product portfolio.

With more than 400 publications in prominent peer-reviewed medical journals including *JAMA*, *JACC*, *Circulation*, *the American Journal of Cardiology*, and *Heart*, the HeartFlow technology has been proven across diverse patient populations. These clinical activities have included a series of large, multi-center global trials encompassing over 10,000 patients worldwide.

**ROBUST EVIDENCE**

- » 16 clinical trials and registries addressing accuracy and outcomes
- » 100+ investigator-initiated studies
- » 400+ peer-reviewed publications
- » Demonstrated safety with long-term data out to 5 years

**AREAS OF RESEARCH**

» Pre-TAVR	» Preventative Screening
» ACS - NSTEMI	» Pediatrics
» Heart Transplant	» Neurovascular
» Emergency Department	» Renal Failure
» Pre-operative Cardiac Evaluation	» PAD

\*HeartFlow is interested in exploring the use of FFR<sub>CT</sub> in these populations



# Exceptional Clinical Results



Time and time again, HeartFlow demonstrates unmatched non-invasive diagnostic performance and accuracy, alongside cost-effectiveness and efficacy.



**Higher diagnostic accuracy**  
than other common non-invasive  
cardiac tests<sup>3</sup>



**40%** reduction in layered testing<sup>5</sup>



**83%** of avoidable coronary  
angiograms cancelled<sup>4</sup>



**Dominates functional testing in**  
cost-effectiveness analysis<sup>6</sup>




**36%** improvement in  
revascularization efficiency<sup>5</sup>

# Best-in-class Technology



- » Patient-specific Interactive 3D Model
- » Best-in-class medical image analysis
- » Advanced deep learning (AI) methodology to precisely extract coronary anatomy
- » AI trained on millions of CT images carefully annotated by expert analysts
- » Physics-based computational models assess pressure and flow changes in coronary arteries
- » HIPAA and SOC 2 Type II compliant, HITRUST certified
- » Secure cloud infrastructure, including encrypted transmission of image data and protected health information (PHI)
- » Comprehensive IP portfolio of > 370 issued and allowed patents worldwide, covering innovations in cardiovascular medicine, physiology and bioengineering



# Unparalleled Innovation



Bringing together human ingenuity and advanced technology, HeartFlow is developing an integrated solution for comprehensive management of coronary artery disease (CAD). From precise diagnostics to treatment optimization, HeartFlow's integrated solution will shape cardiac care.

## CAD Diagnosis




**CORONARY STENOSIS\***  
Stenosis and Image Quality  
Data for all CTA patients

## CAD Severity Assessment




**INTERACTIVE FFR<sub>CT</sub>**  
Anatomy and  
physiology via  
personalized 3D model




**MYOCARDIAL  
INSIGHTS\***  
% Myocardium  
Affected, Myocardial  
Perfusion Data

## CAD Treatment Optimization



**PLAQUE ANALYSIS\***  
Plaque Visualization  
and Quantification



**INTERVENTION  
PLANNING**  
Planning Cath  
Procedures & Virtual  
Revascularization

\*Currently in development and not available for clinical use.



# Outstanding Customer Experience





# HeartFlow is Leading the Way



- » Secured regulatory clearance to commercialize first-of-kind, AI-enabled, non-invasive diagnostic simulation of FFR<sub>CT</sub> (2011: CE Mark, 2014: US FDA De Novo Clearance, 2017: Japan PMDA approval)
- » Established Medicare New Technology Ambulatory Payment Classification to reimburse hospitals, effective Jan 1, 2018



- » 92% of people in the US have insurance coverage for HeartFlow
- » 70,000+ patients received a HeartFlow Analysis
- » Adopted by over 350 hospitals worldwide, including 75% of the top 50 heart hospitals in the US<sup>7</sup>

REFERENCES

1. Nørgaard, et al. Euro J Radiol 2015. Jung, et al. Euro Heart J 2008. Melikian, et al. JACC Cardiovasc Interv 2010. Koo, et al. JACC 2011. Min, et al. J Am Med Assoc 2012. Nørgaard, et al. JACC 2014. Danad, et al. JAMA Cardiol 2017. Driessen, et al. JACC 2019.

2. Data on file at HeartFlow. November 2020.

3. Driessen, et al. J Am Coll Cardiol 2019. Nørgaard, et al. J Am Cardiol 2014.

4. Douglas, et al. J Am Coll Cardiol 2016.

5. Curzen, et al. TCTConnect 2020.

6. Hoffman, et al. TCT 2019. Manuscript under review.

7. Top 50 Heart Hospitals as designated by US News and World Report

